| Patient Information | Specimen Information | Client Information |
|---|---|---|
| | | |

**COMMENTS:** FASTING:YES

| Test Name | In Range | Out Of Range | Reference Range | Lab |
|---|---|---|---|---|
| THYROID PANEL WITH TSH | | | | |
| THYROID PANEL | | | | TP |
| T3 UPTAKE | 29 | | 22-35 % | |
| T4 (THYROXINE), TOTAL | 7.8 | | 5.1-11.9 mcg/dL | |
| FREE T4 INDEX (T7) | 2.3 | | 1.4-3.8 | |
| TSH | 3.38 | | mIU/L | TP |
| | | | Reference Range | |
| | | | > or = 20 Years 0.40-4.50 | |
| | | | Pregnancy Ranges | |
| | | | First trimester 0.26-2.66 | |
| | | | Second trimester 0.55-2.73 | |
| | | | Third trimester 0.43-2.91 | |
| LIPID PANEL, STANDARD | | | | |
| CHOLESTEROL, TOTAL | 173 | | <200 mg/dL | TP |
| HDL CHOLESTEROL | 58 | | > OR = 50 mg/dL | TP |
| TRIGLYCERIDES | 59 | | <150 mg/dL | TP |
| **LDL-CHOLESTEROL** | | **101 H** | mg/dL (calc) | TP |
| Reference range: <100 | | | | |
| Desirable range <100 mg/dL for primary prevention; <70 mg/dL for patients with CHD or diabetic patients with > or = 2 CHD risk factors. | | | | |
| LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) | | | | |
| CHOL/HDLC RATIO | 3.0 | | <5.0 (calc) | TP |
| NON HDL CHOLESTEROL | 115 | | <130 mg/dL (calc) | TP |
| For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. | | | | |
| COMPREHENSIVE METABOLIC PANEL | | | | TP |
| GLUCOSE | 89 | | 65-99 mg/dL | |
| | | | Fasting reference interval | |
| UREA NITROGEN (BUN) | 17 | | 7-25 mg/dL | |
| CREATININE | 0.76 | | 0.50-1.03 mg/dL | |
| EGFR | 95 | | > OR = 60 mL/min/1.73m2 | |
| BUN/CREATININE RATIO | SEE NOTE: | | 6-22 (calc) | |
| Not Reported: BUN and Creatinine are within reference range. | | | | |
| SODIUM | 140 | | 135-146 mmol/L | |
| POTASSIUM | 4.6 | | 3.5-5.3 mmol/L | |

| Patient Information | Specimen Information | Client Information |
|---|---|---|
| | | |

| Test Name | In Range | Out Of Range | Reference Range | Lab |
|---|---|---|---|---|
| CHLORIDE | 107 | | 98-110 mmol/L | |
| CARBON DIOXIDE | 26 | | 20-32 mmol/L | |
| CALCIUM | 9.6 | | 8.6-10.4 mg/dL | |
| PROTEIN, TOTAL | 6.9 | | 6.1-8.1 g/dL | |
| ALBUMIN | 4.3 | | 3.6-5.1 g/dL | |
| GLOBULIN | 2.6 | | 1.9-3.7 g/dL (calc) | |
| ALBUMIN/GLOBULIN RATIO | 1.7 | | 1.0-2.5 (calc) | |
| BILIRUBIN, TOTAL | 0.7 | | 0.2-1.2 mg/dL | |
| ALKALINE PHOSPHATASE | 66 | | 37-153 U/L | |
| AST | 12 | | 10-35 U/L | |
| ALT | 7 | | 6-29 U/L | |
| MAGNESIUM, RBC | 4.6 | | 4.0-6.4 mg/dL | AMD |
| This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. | | | | |
| PHOSPHATE (AS PHOSPHORUS) | 3.8 | | 2.5-4.5 mg/dL | TP |
| URIC ACID | 5.3 | | 2.5-7.0 mg/dL | TP |
| Therapeutic target for gout patients: <6.0 mg/dL | | | | |
| LD | 128 | | 120-250 U/L | TP |
| GGT | 12 | | 3-70 U/L | TP |
| T4, FREE | 1.2 | | 0.8-1.8 ng/dL | TP |
| T3, FREE | 3.7 | | 2.3-4.2 pg/mL | TP |
| CBC (INCLUDES DIFF/PLT) | | | | TP |
| WHITE BLOOD CELL COUNT | 7.8 | | 3.8-10.8 Thousand/uL | |
| RED BLOOD CELL COUNT | 4.36 | | 3.80-5.10 Million/uL | |
| HEMOGLOBIN | 13.5 | | 11.7-15.5 g/dL | |
| HEMATOCRIT | 40.7 | | 35.0-45.0 % | |
| MCV | 93.3 | | 80.0-100.0 fL | |

| Patient Information | Specimen Information | Client Information |
|---|---|---|
| | | |

| Test Name | In Range | Out Of Range | Reference Range | Lab |
|---|---|---|---|---|
| MCH | 31.0 | | 27.0-33.0 pg | |
| MCHC | 33.2 | | 32.0-36.0 g/dL | |
| RDW | 11.8 | | 11.0-15.0 % | |
| PLATELET COUNT | 287 | | 140-400 Thousand/uL | |
| MPV | 10.8 | | 7.5-12.5 fL | |
| ABSOLUTE NEUTROPHILS | 4103 | | 1500-7800 cells/uL | |
| ABSOLUTE LYMPHOCYTES | 2972 | | 850-3900 cells/uL | |
| ABSOLUTE MONOCYTES | 593 | | 200-950 cells/uL | |
| ABSOLUTE EOSINOPHILS | 94 | | 15-500 cells/uL | |
| ABSOLUTE BASOPHILS | 39 | | 0-200 cells/uL | |
| NEUTROPHILS | 52.6 | | % | |
| LYMPHOCYTES | 38.1 | | % | |
| MONOCYTES | 7.6 | | % | |
| EOSINOPHILS | 1.2 | | % | |
| BASOPHILS | 0.5 | | % | |
| IRON, TOTAL | 121 | | 45-160 mcg/dL | TP |
| FERRITIN | 54 | | 16-232 ng/mL | TP |

**PERFORMING SITE:**

AMD QUEST DIAGNOSTICS/NICHOLS CHANTILLY, 14225 NEWBROOK DRIVE, CHANTILLY, VA 20151-2228 Laboratory Director: PATRICK W. MASON,MD,PHD, CLIA: 49D0221801

TP QUEST DIAGNOSTICS-TAMPA, 4225 E. FOWLER AVE, TAMPA, FL 33617-2026 Laboratory Director: WESTON H ROTHROCK,MD, CLIA: 10D0291120